BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 37318134)

  • 1. Gut microbiota changes associated with
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    Gut Microbes; 2023; 15(1):2223345. PubMed ID: 37318134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota restoration therapies for recurrent
    DuPont HL; DuPont AW; Tillotson GS
    Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
    Lavoie T; Appaneal HJ; LaPlante KL
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S487-S496. PubMed ID: 38051970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent
    Wang Y; Hunt A; Danziger L; Drwiega EN
    Antibiotics (Basel); 2024 May; 13(5):. PubMed ID: 38786164
    [No Abstract]   [Full Text] [Related]  

  • 7. Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent
    Wei S; Bahl MI; Baunwall SMD; Dahlerup JF; Hvas CL; Licht TR
    Gut Microbes; 2022; 14(1):2084306. PubMed ID: 36519447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the gut microbiome in colonization resistance and recurrent
    Seekatz AM; Safdar N; Khanna S
    Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SER-109 (VOWST
    Blair HA
    Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
    Chopra T
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigating changes in
    Durham SH; Le P; Cassano AT
    J Manag Care Spec Pharm; 2020 Dec; 26(12-a Suppl):S3-S23. PubMed ID: 33533699
    [No Abstract]   [Full Text] [Related]  

  • 12. Current and future trends in clostridioides (clostridium) difficile infection management.
    Khanna S; Gerding DN
    Anaerobe; 2019 Aug; 58():95-102. PubMed ID: 31054313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
    Orenstein R
    Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutics for
    Khanna S; Voth E
    Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of
    Eliakim-Raz N; Bishara J
    Hum Vaccin Immunother; 2019; 15(6):1453-1456. PubMed ID: 29781761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbial ecology between
    Kamiya S
    Biosci Microbiota Food Health; 2023; 42(4):229-235. PubMed ID: 37791342
    [No Abstract]   [Full Text] [Related]  

  • 18. The development of live biotherapeutics against
    Zhang Y; Saint Fleur A; Feng H
    Gut Microbes; 2022; 14(1):2052698. PubMed ID: 35319337
    [No Abstract]   [Full Text] [Related]  

  • 19. Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
    Jan N; Hays RA; Oakland DN; Kumar P; Ramakrishnan G; Behm BW; Petri WA; Marie C
    mSphere; 2021 Oct; 6(5):e0066921. PubMed ID: 34704776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional profile of host microbiome indicates
    Nzabarushimana E; Tang H
    Gut Microbes; 2022; 14(1):2135963. PubMed ID: 36289064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.